SVETLANA FOMIN
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism EAST SYRACUSE, NY NPI 1326219924
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism NY Medtronic, Inc. All categories
General Payments — all program years on this page
$3,842.71
- Category: General Payments
- Program years: PY2018–2024
- Record count: 268
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,839.58 across 93 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,839.58 | 93 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $246.07 | 5 |
| Lilly USA, LLC | $208.89 | 20 |
| Novo Nordisk AS | $195.30 | 13 |
| Amgen Inc. | $181.13 | 7 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $156.63 | 7 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $114.36 | 5 |
| Abbott Laboratories | $74.93 | 4 |
| Alexion Pharmaceuticals, Inc. | $68.62 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $67.02 | 4 |
| PFIZER INC. | $50.56 | 2 |
| SANOFI-AVENTIS U.S. LLC | $50.02 | 2 |
| BETA BIONICS, INC. | $48.14 | 2 |
| DEXCOM, INC. | $45.39 | 2 |
| Insulet Corporation | $43.46 | 2 |
| Amphastar Pharmaceuticals, Inc. | $40.05 | 2 |
| Amneal Pharmaceuticals LLC | $37.67 | 2 |
| IBSA Pharma Inc. | $34.23 | 2 |
| Astellas Pharma US Inc | $33.54 | 1 |
| Ultragenyx Pharmaceutical Inc. | $23.64 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $22.12 | 1 |
| Radius Health, Inc. | $20.00 | 1 |
| Xeris Pharmaceuticals, Inc. | $19.91 | 1 |
| Inspire Medical Systems, Inc. | $15.30 | 1 |
| CeQur Corporation | $14.87 | 1 |
| ABBVIE INC. | $14.51 | 1 |
| MannKind Corporation | $13.22 | 1 |
By program year
Records — PY2024 (93)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.